All Posts

On October 16, four patents for Allergan’s second best-selling product, the dry-eye treatment Restasis, were invalidated by a federal judge in a Hatch-Waxman Act case for patent infringement. United States Circuit Judge William C. Bryson of the Eastern District of Texas ruled that although Allergan had proved the defendants’ infringement of the Restasis patents at […]